Related Experiment Video
Updated: Oct 4, 2025
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.1K
[Genotype-guided antithrombotic therapy]
Wout W A van den Broek1,2, Jaouad Azzahhafi1, Ron H N van Schaik3
1St. Antonius Ziekenhuis, afd. Cardiologie, Nieuwegein.
Nederlands Tijdschrift Voor Geneeskunde
|February 9, 2022
Summary
Genotype-guided clopidogrel treatment shows clinical benefits but lacks guideline support. Determining CYP2C19 genotype is recommended for high-risk patients to prevent ischemic events.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Cardiology
Background:
- Current literature suggests clinical and cost-effective benefits of genotype-guided clopidogrel treatment.
- However, this strategy is not universally recommended in clinical guidelines due to insufficient evidence in cardiology, neurology, and vascular surgery.
Purpose of the Study:
- To evaluate the role of pharmacogenetics in guiding clopidogrel treatment.
- To address the need for personalized medicine and identify high-risk patient populations for genotype testing.
Main Methods:
- Literature review on genotype-guided clopidogrel therapy.
- Analysis of clinical evidence for CYP2C19 genotype testing.
- Consideration of implementation challenges and cost implications.
Main Results:
- Genotype-guided treatment demonstrates clinical and cost-effective advantages.
- Evidence remains insufficient for broad guideline recommendations.
- Identifying CYP2C19 genotype is valuable for patients with coronary artery disease and high bleeding risk.
Conclusions:
- Pharmacogenetics, particularly CYP2C19 genotyping, is increasingly important for personalized medicine.
- Specialists should consider CYP2C19 genotyping for clopidogrel therapy in patients at high risk of recurrent ischemic events.
- Further studies are needed to solidify guideline recommendations and address implementation challenges.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
44
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
44
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
975
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
975
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
688
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
688
01:26Atherosclerosis III: Management
58
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
58
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
268
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
268